tranilast has been researched along with Scleroderma--Localized* in 4 studies
4 other study(ies) available for tranilast and Scleroderma--Localized
| Article | Year |
|---|---|
A case of atypical localized scleroderma presenting with pseudoainhum: treatment with tranilast, an anti-fibrotic agent.
Topics: Ainhum; Arm; Diagnosis, Differential; Female; Humans; Middle Aged; ortho-Aminobenzoates; Platelet Aggregation Inhibitors; Scleroderma, Localized | 1996 |
Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture.
We have previously reported that tranilast, an anti-allergic agent, specifically suppresses collagen synthesis in normal skin fibroblasts and to a greater extent in keloid fibroblasts. We found in this study that the specific suppression of collagen synthesis by tranilast was limited to the fibroblasts with a high passage number (passage 8-10). In normal skin fibroblasts with a low passage number (passage 1-2), tranilast exerted no significant effect on collagen synthesis. This was also observed with scleroderma and keloid fibroblasts. This result suggests that inhibition of collagen by tranilast will be dependent on in vitro cellular aging and that serial cell passages result in the loss of the cell phenotype resistant to tranilast effect. Topics: Cells, Cultured; Cellular Senescence; Collagen; Fibroblasts; Humans; Keloid; ortho-Aminobenzoates; Scleroderma, Localized | 1995 |
Treatment of linear localized scleroderma with the anti-allergic drug, tranilast.
A 14-year-old boy with linear localized scleroderma had a dramatic improvement in contractures after treatment with N-(3',4'-dimethoxycinnamoyl) anthranilic acid (tranilast, Rizaben). The observation that this anti-allergic drug was effective in localized scleroderma lends further support to the concept that mast cells play a role in increased collagen synthesis in this disease. Topics: Adolescent; Histamine H1 Antagonists; Humans; Leg; Male; Movement; ortho-Aminobenzoates; Scleroderma, Localized; Toe Joint | 1994 |
Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts.
Effects of tranilast, N-(3,4-dimethoxycinnamoyl)anthranilic acid, on collagen synthesis in cultured human skin fibroblasts were studied. Tranilast was found to inhibit collagen synthesis in a dose-dependent manner to a maximum of 55% at 300 microM during 48 h of treatment; the synthesis of type I and type III collagens was equally affected. Administered simultaneously or subsequently, tranilast reduced the stimulatory effect of transforming growth factor beta 1 (2.5 ng/ml) on collagen synthesis without affecting the accompanying stimulation of noncollagen protein synthesis. It did not affect prolyl or lysyl hydroxylase activity in vitro and in cells. The content of pro alpha 1(I) collagen mRNA was decreased 60% by tranilast. Tranilast prevented the TGF beta 1-mediated increase in pro alpha 1(I) collagen mRNA. These results indicate that tranilast specifically inhibits collagen production at a pretranslational level by interfering with TGF beta 1 effects. Tranilast also inhibited collagen synthesis in scleroderma fibroblasts to the same extent and in keloid fibroblasts to a greater extent than in normal fibroblasts, attesting to its therapeutic potential as an antifibrotic drug. Topics: Adolescent; Adult; Aged; Cells, Cultured; Collagen; Female; Fibroblasts; Histamine H1 Antagonists; Humans; Keloid; Male; Middle Aged; ortho-Aminobenzoates; Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase; Procollagen-Proline Dioxygenase; RNA, Messenger; Scleroderma, Localized; Skin | 1994 |